USMF logo

Institutional Repository in Medical Sciences
of Nicolae Testemitanu State University of Medicine and Pharmacy
of the Republic of Moldova
(IRMS – Nicolae Testemitanu SUMPh)

Biblioteca Stiintifica Medicala
DSpace

University homepage  |  Library homepage

 
 
Please use this identifier to cite or link to this item: http://hdl.handle.net/20.500.12710/27359
Full metadata record
DC FieldValueLanguage
dc.contributor.authorȘcerbatiuc, Cristina-
dc.date.accessioned2024-08-19T08:16:50Z-
dc.date.available2024-08-19T08:16:50Z-
dc.date.issued2024-
dc.identifier.citationȘCERBATIUC, Cristina. Anti-vascular endothelial growth factor (anti-VEGF): its function in proliferative diabetic retinopathy management. In: Revista de Științe ale Sănătății din Moldova = Moldovan Journal of Health Sciences. 2024, nr. 2(11), pp. 62-67. ISSN 2345-1467. https://doi.org/10.52645/MJHS.2024.2.08en_US
dc.identifier.issn2345-1467-
dc.identifier.urihttps://cercetare.usmf.md/sites/default/files/inline-files/Cristina%20%C8%98cerbatiuc%20Anti-vascular%20endothelial%20growth%20factor%20%28anti-VEGF%29%20its%20function%20in%20proliferative%20diabetic%20retinopathy%20management.pdf-
dc.identifier.urihttps://doi.org/10.52645/MJHS.2024.2.08-
dc.identifier.urihttp://repository.usmf.md/handle/20.500.12710/27359-
dc.description.abstractIntroduction. Among working-age adults, diabetes is a primary cause of visual impairment. Pan-retinal photocoagulation, the standard treatment for proliferative diabetic retinopathy, is effective but comes with well-established adverse effects, including limitations on the peripheral visual field. The mechanism of vascular proliferation is thought to be triggered by vascular endothelial growth factor (anti-VEGF). Anti-VEGF medications have been studied extensively in the treatment of diabetic macular edema, and the results suggest that treatment with anti-VEGF medications causes a decrease in diabetic retinopathy. Anti-VEGF therapies can be used to treat underlying proliferative diabetic retinopathy in cases of vitreous bleeding when platelet-rich plasma cannot be used, delaying, or reducing the necessity for a vitrectomy. However, the limitations of anti-VEGF therapy require careful patient selection and constant observation. Recent clinical trials and recommendations for the use of anti-VEGF in proliferative diabetic retinopathy are presented in this review. Material and methods. The effectiveness of anti-VEGF medicines in the treatment of diabetic retinopathy was the subject of a comprehensive review of the scientific and medical literature. A structured search was performed in the PubMed, Scopus, and HINARI databases, considering relevant articles published in the last 10 years. The search terms used (in English) were: “angiogenesis inhibitors”, “anti-VEGF”, “pan-retinal photocoagulation”, “intravitreal injection”, “diabetic retinopathy”. Accurate diagnosis, side effects, quality of life, and patient satisfaction were analyzed and compared for each treatment option. Results. Anti-VEGF treatments have been demonstrated to be beneficial in reducing macular edema, enhancing visual acuity, and slowing the advancement of diabetic retinopathy. While generally safe, different anti-VEGF medicines have varied side effects profiles. Conclusion. When choosing an anti-VEGF treatment for diabetic retinopathy, factors such as patient satisfaction, quality of life, side effects, and correct diagnosis should be taken into account. While anti-VEGF treatments show promise, further study is required to fully understand their advantages and disadvantages and to optimize their application.en_US
dc.language.isoenen_US
dc.publisherInstituţia Publică Universitatea de Stat de Medicină şi Farmacie „Nicolae Testemiţanu” din Republica Moldovaen_US
dc.relation.ispartofRevista de Științe ale Sănătății din Moldova = Moldovan Journal of Health Sciencesen_US
dc.subjectangiogenesis inhibitorsen_US
dc.subjectanti-VEGFen_US
dc.subjectpan-retinal photocoagulationen_US
dc.subjectintravitreal injectionen_US
dc.subjectdiabetic retinopathyen_US
dc.subject.ddcUDC: 617.735-007.281:616.379-008.64en_US
dc.titleAnti-vascular endothelial growth factor (anti-VEGF): its function in proliferative diabetic retinopathy managementen_US
dc.typeArticleen_US
Appears in Collections:Revista de Științe ale Sănătății din Moldova : Moldovan Journal of Health Sciences 2024 nr. 2(11)



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

 

Valid XHTML 1.0! DSpace Software Copyright © 2002-2013  Duraspace - Feedback